Literature DB >> 27943467

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.

D V Quon1, R Klamroth2, R Kulkarni3, A D Shapiro4, R I Baker5, G Castaman6, B A Kerlin7, E Tsao8, G Allen8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27943467     DOI： 10.1111/hae.13125

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

Review 1.  Efmoroctocog Alfa: A Review in Haemophilia A.

Authors:  James E Frampton
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 2.  Achieving the unimaginable: Health equity in haemophilia.

Authors:  Mark W Skinner; Diane Nugent; Pam Wilton; Brian O'Mahony; Gerry Dolan; Jamie O'Hara; Erik Berntorp
Journal:  Haemophilia       Date:  2019-11-13       Impact factor: 4.287

3.  Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.

Authors:  Anshu Shrestha; Jun Su; Nanxin Li; Christopher Barnowski; Nisha Jain; Katie Everson; Anupam Bapu Jena; Katharine Batt
Journal:  Res Pract Thromb Haemost       Date:  2020-12-30

Review 4.  Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors:  Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal:  Eur J Haematol       Date:  2021-03-31       Impact factor: 2.997

Review 5.  Efmoroctocog Alfa: A Review in Haemophilia A.

Authors:  James E Frampton
Journal:  Drugs       Date:  2021-11-07       Impact factor: 9.546

Review 6.  Emerging therapies for hemophilia: controversies and unanswered questions.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  F1000Res       Date:  2018-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.